The emergence of extracellular vesicles in urology: fertility, cancer, biomarkers and targeted pharmacotherapy

References

• Cocucci E, Racchetti G, Meldolesi J. Shedding microvesicles: artefacts no more. Trends Cell Biol. 2009; 19: 43–51. [PubMed Abstract].
   Google Scholar
• Lötvall J, Hill AF, Hochberg F, Buzás EI, Di Vizio D, Gardiner C. Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles. J Extracell Vesicles. 2014; 3: 26913. doi: http://dx.doi.org/10.3402/jev.v3.26913.
   Google Scholar
• Thery C, Ostrowski M, Segura E. Membrane vesicles as conveyors of immune responses. Nat Rev Immunol. 2009; 9: 581–93. [PubMed Abstract].
   Google Scholar
• El Andaloussi S, Mäger I, Breakefield XO, Wood MJ. Extracellular vesicles: biology and emerging therapeutic opportunities. Nat Rev Drug Discov. 2013; 12: 347–57. [PubMed Abstract].
   Google Scholar
• Quesenberry PJ, Aliotta JM. The paradoxical dynamism of marrow stem cells: considerations of stem cells, niches, and microvesicles. Stem Cell Rev. 2008; 4: 137–47. [PubMed Abstract].
   Google Scholar
• Ratajczak J, Wysoczynski M, Hayek F, Janowska-Wieczorek A, Ratajczak MZ. Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication. Leukemia. 2006; 20: 1487–95. [PubMed Abstract].
   Google Scholar
• Camussi G, Deregibus MC, Bruno S, Cantaluppi V, Biancone L. Exosomes/microvesicles as a mechanism of cell-to-cell communication. Kidney Int. 2010; 78: 838–48. [PubMed Abstract].
   Google Scholar
• Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T et al. Cancer statistics, 2008. CA Cancer J Clin. 2008; 58: 71–96. [PubMed Abstract].
   Google Scholar
• Horwich A, Huddart R. Retroperitoneal lymph-node dissection after chemotherapy for germ cell cancer in patients with elevated tumor markers. Nat Clin Pract Urol. 2006; 3: 250–1. [PubMed Abstract].
   Google Scholar
• Ronquist G, Hedstrom M. Restoration of detergent-inactivated adenosine triphosphatase activity of human prostatic fluid with concanavalin A. Biochim Biophys Acta. 1977; 483: 483–6. [PubMed Abstract].
   Google Scholar
• Ronquist G, Brody I, Gottfries A, Stegmayr B. An Mg2+ and Ca2 + -stimulated adenosine triphosphatase in human prostatic fluid: part I. Andrologia. 1978; 10: 261–72. [PubMed Abstract].
   Google Scholar
• Ronquist G, Brody I, Gottfries A, Stegmayr B. An Mg2+ and Ca2 + -stimulated adenosine triphosphatase in human prostatic fluid: part II. Andrologia. 1978; 10: 427–33. [PubMed Abstract].
   Google Scholar
• Ronquist G, Brody I. The prostasome: its secretion and function in man. Biochem Biophys Acta. 1985; 822: 203–18. [PubMed Abstract].
   Google Scholar
• Arienti G, Carlini E, Saccardi C, Palmerini CA. Role of human prostasomes in the activation of spermatozoa. J Cell Mol Med. 2004; 8: 77–84. [PubMed Abstract].
   Google Scholar
• Park KH, Kim BJ, Kang J, Nam TS, Lim JM, Kim HT et al. Ca2+ signaling tools acquired from prostasomes are required for progesterone-induced sperm motility. Sci Signal. 2011; 4: ra31. [PubMed Abstract].
   Google Scholar
• Skibinski G, Kelly RW, Harkiss D, James K. Immunosuppression by human seminal plasma – extracellular organelles (prostasomes) modulate activity of phagocytic cells. Am J Reprod Immunol. 1992; 28: 97–103. [PubMed Abstract].
   Google Scholar
• Ronquist G. Prostasomes are mediators of intercellular communication: from basic research to clinical implications. J Intern Med. 2012; 271: 400–13. [PubMed Abstract].
   Google Scholar
• Rooney IA, Atkinson JP, Krul ES, Schonfeld G, Polakoski K, Saffitz JE et al. Physiologic relevance of the membrane attack complex inhibitory protein CD59 in human seminal plasma: CD59 is present on extracellular organelles (prostasomes), binds cell membranes, and inhibits complement-mediated lysis. J Exp Med. 1993; 177: 1409–20. [PubMed Abstract].
   Google Scholar
• Al-Dossary AA, Strehler EE, Martin-Deleon PA. Expression and secretion of plasma membrane Ca2 + -ATPase 4a (PMCA4a) during murine estrus: association with oviductalexosomes and uptake in sperm. PLoS One. 2013; 8: e80181. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Babiker AA, Ronquist G, Nilsson B, Ekdahl KN. Overexpression of ecto-protein kinases in prostasomes of metastatic cell origin. Prostate. 2006; 66: 675–86. [PubMed Abstract].
   Google Scholar
• Babiker AA, Nilsson B, Ronquist G, Carlsson L, Ekdahl KN. Transfer of functional prostasomal CD59 of metastatic prostatic cancer cell origin protects cells against complement attack. Prostate. 2005; 62: 105–14. [PubMed Abstract].
   Google Scholar
• Angelucci A, D'Ascenzo S, Festuccia C, Gravina GL, Bologna M, Dolo V et al. Vesicle-associated urokinase plasminogen activator promotes invasion in prostate cancer cell lines. Clin Exp Metastasis. 2000; 18: 163–70. [PubMed Abstract].
   Google Scholar
• Castellana D, Zobairi F, Martinez MC, Panaro MA, Mitolo V, Freyssinet JM et al. Membrane microvesicles as actors in the establishment of a favorable prostatic tumoral niche: a role for activated fibroblasts and CX3CL1-CX3CR1 axis. Cancer Res. 2009; 69: 785–93. [PubMed Abstract].
   Google Scholar
• Lundholm M, Schröder M, Nagaeva O, Baranov V, Widmark A, Mincheva-Nilsson L et al. Prostate tumor-derived exosomes down-regulate NKG2D expression on natural killer cells and CD8+ T cells: mechanism of immune evasion. PLoS One. 2014; 9: e108925. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Abe K, Shoji M, Chen J, Bierhaus A, Danave I, Micko C et al. Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. Proc Natl Acad Sci USA. 1999; 96: 8663–8. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Casimiro S, Guise TA, Chirgwin J. The critical role of the bone microenvironment in cancer metastases. Mol Cell Endocrinol. 2009; 310: 71–81. [PubMed Abstract].
   Google Scholar
• Clarke NW, Hart CA, Brown MD. Molecular mechanisms of metastasis in prostate cancer. Asian J Androl. 2009; 11: 57–67. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Itoh T, Ito Y, Ohtsuki Y, Ando M, Tsukamasa Y, Yamada N et al. Microvesicles released from hormone-refractory prostate cancer cells facilitate mouse pre-osteoblast differentiation. J Mol Histol. 2012; 43: 509–15. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Renzulli JF 2nd, Del Tatto M, Dooner G, Aliotta J, Goldstein L, Dooner M et al. Microvesicle induction of prostate specific gene expression in normal human bone marrow cells. J Urol. 2010; 184: 2165–71. [PubMed Abstract].
   Google Scholar
• Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR et al. Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012; 104: 125–32. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Carlsson SV, Holmberg E, Moss SM, Roobol MJ, Schroder FH, Tammela TL et al. No excess mortality after prostate biopsy: results from the European Randomized Study of Screening for Prostate Cancer. BJU Int. 2011; 107: 1912–17. [PubMed Abstract].
   Google Scholar
• Ilic D, Neuberger MM, Djulbegovic M, Dahm P. Screening for prostate cancer. Cochrane Database Syst Rev. 2013; 1: CD004720. [PubMed Abstract].
   Google Scholar
• Ercole B, Parekh DJ. Methods to predict and lower the risk of prostate cancer. Sci World J. 2011; 11: 742–8.
   Web of Science ®Google Scholar
• Reed AB, Parekh DJ. Biomarkers for prostate cancer detection. Expert Rev Anticancer Ther. 2010; 10: 103–14. [PubMed Abstract].
   Google Scholar
• Tavoosidana G, Ronquist G, Darmanis S, Yan J, Carlsson L, Wu D et al. Multiple recognition assay reveals prostasomes as promising plasma biomarkers for prostate cancer. Proc Natl Acad Sci USA. 2011; 108: 8809–14. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Sandvig K, Llorente A. Proteomic analysis of microvesicles released by the human prostate cancer cell line PC-3. Mol Cell Proteomics. 2012; 11: M111.012914. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Deryugina EI, Conn EM, Wortmann A, Partridge JJ, Kupriyanova TA, Ardi VC et al. Functional role of cell surface CUB domain-containing protein 1 in tumor cell dissemination. Mol Cancer Res. 2009; 7: 1197–211. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Siva AC, Wild MA, Kirkland RE, Nolan MJ, Lin B, Maruyama T. Targeting CUB Domain Containing Protein 1 with a Monoclonal Antibody Inhibits Metastasis in a Prostate Cancer Model. Cancer Res. 2008; 68: 3759. 66.
   PubMed Web of Science ®Google Scholar
• Khan S, Jutzy JM, Valenzuela MM, Turay D, Aspe JR, Ashok A et al. Plasma-derived exosomal survivin, a plausible biomarker for early detection of prostate cancer. PLoS One. 2012; 7: e46737. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Gabriel K, Ingram A, Austin R, Kapoor A, Tang D, Majeed F et al. Regulation of the tumor suppressor PTEN through exosomes: a diagnostic potential for prostate cancer. PLoS One. 2013; 8(7): 70047.
   PubMed Web of Science ®Google Scholar
• Ang J, Lijovic M, Ashman LK, Kan K, Frauman AG. CD151 protein expression predicts the clinical outcome of low-grade primary prostate cancer better than histologic grading: a new prognostic indicator?. Cancer Epidemiol Biomarkers Prev. 2004; 13: 1717–21. [PubMed Abstract].
   Google Scholar
• Huang X, Yuan T, Liang M, Du M, Xia S, Dittmar R. Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer. Eur Urol. 2015; 67: 33–41. [PubMed Abstract].
   Google Scholar
• Corcoran C, Rani S, O'Driscoll L. miR-34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression. Prostate. 2014; 74: 1320–34. [PubMed Abstract].
   Google Scholar
• Bryant RJ, Pawlowski T, Catto JWF, Marsden G, Vessella RL, Rhees B et al. Changes in circulating microRNA levels associated with prostate cancer. British Journal of Cancer. 2012; 106(4): 768–774. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 2008; 105: 10513–18. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Brase JC, Johannes M, Schlomm T, Fälth M, Haese A, Steuber T et al. Circulating miRNAs are correlated with tumortumour progression in prostate cancer. Int. J. Cancer. 2011; 128: 608–616. [PubMed Abstract].
   Google Scholar
• Zhou H, Pisitkun T, Aponte A, Yuen PS, Hoffert JD, Yasuda H et al. Exosomal fetuin-A identified by proteomics: a novel urinary biomarker for detecting acute kidney injury. Kidney Int. 2006; 70: 1847–57. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Sonoda H, Takase H, Dohi Y, Kimura G. Uric acid levels predict future development of chronic kidney disease. Am J Nephrol. 2011; 33: 352–7. [PubMed Abstract].
   Google Scholar
• Fleissner F, Goerzig Y, Haverich A, Thum T. Microvesicles as novel biomarkers and therapeutic targets in transplantation medicine. Am J Transplant. 2012; 12: 289–97. [PubMed Abstract].
   Google Scholar
• Grange C, Tapparo M, Bruno S, Chatterjee D, Quesenberry PJ, Tetta C et al. Biodistribution of mesenchymal stem cell-derived extracellular vesicles in a model of acute kidney injury monitored by optical imaging. Int J Mol Med. 2014; 33: 1055–63. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Chow TF, Youssef YM, Lianidou E, Romaschin AD, Honey RJ, Stewart R et al. Differential expression profiling of microRNAs and their potential involvement in renal cell carcinoma pathogenesis. Clin Biochem. 2010; 43: 150–8. [PubMed Abstract].
   Google Scholar
• Tickoo SK, Lee MW, Eble JN, Amin M, Christopherson T, Zarbo RJ et al. Ultrastructural observations on mitochondria and microvesicles in renal oncocytoma, chromophobe renal cell carcinoma, and eosinophilic variant of conventional (clear cell) renal cell carcinoma. Am J Surg Pathol. 2000; 24: 1247–56. [PubMed Abstract].
   Google Scholar
• Grange C, Tapparo M, Collino F, Vitillo L, Damasco C, Deregibus MC et al. Microvesicles released from human renal cancer stem cells stimulate angiogenesis and formation of lung premetastatic niche. Cancer Res. 2011; 71: 5346–56. [PubMed Abstract].
   Google Scholar
• Del Boccio P, Raimondo F, Pieragostino D, Morosi L, Cozzi G., Sacchetta P et al. A hyphenated microLC-Q-TOF-MS platform for exosomallipidomics investigations: application to RCC urinary exosomes. Electrophoresis. 2012; 33: 689–696. [PubMed Abstract].
   Google Scholar
• Raimondo F, Morosi L, Corbetta S, Chinello C, Brambilla P, Della Mina P et al. Differential protein profiling of renal cell carcinoma urinary exosomes. Mol Biosyst. 2013; 9: 1220–33. [PubMed Abstract].
   Google Scholar
• Shariat SF, Chromecki TF, Cha EK, Karakiewicz PI, Sun M, Fradet Y et al. Risk stratification of organ confined bladder cancer after radical cystectomy using cell cycle related biomarkers. J Urol. 2012; 187: 457–62. [PubMed Abstract].
   Google Scholar
• Smalley DM, Sheman NE, Nelson K, Theodorescu D. Isolation and identification of potential urinary microparticle biomarkers of bladder cancer. J Proteome Res. 2008; 7: 2088–96. [PubMed Abstract].
   Google Scholar
• Welton JL, Khanna S, Giles PJ, Brennan P, Brewis IA, Staffurth J et al. Proteomics Aanalysis of Bbladder Ccancer Eexosomes. Molecular & Cellular Proteomics: MCP. 2010; 9(6): 1324–1338. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Chen CL, Lai YF, Tang P, Chien KY, Yu JS, Tsai CH et al. Comparative and targeted proteomic analyses of urinary microparticles from bladder cancer and hernia patients. J Proteome Res. 2012; 11: 5611–29. [PubMed Abstract].
   Google Scholar
• Ibragimova I, Ibanez de Caceres I, Hoffman AM, Potapova A, Dulaimi E, Al-Saleem T et al. Global reactivation of epigenetically silenced genes in prostate cancer. Cancer Prev Res (Phila). 2010; 3: 1084–92. [PubMed Abstract].
   Google Scholar
• Jeronimo C, Esteller M. DNA methylation markers for prostate cancer with a stem cell twist. Cancer Prev Res (Phila). 2010; 3: 1053–5. [PubMed Abstract].
   Google Scholar
• Perez A, Loizaga A, Arceo R, Lacasa I, Rabade A, Zorroza K et al. A pilot study on the potential of RNA-associated to urinary vesicles as a suitable non-invasive source for diagnostic purposes in bladder cancer. Cancers. 2014; 6(1): 179–192. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Beckham CJ, Olsen J, Yin PN, Wu CH, Ting HJ, Hagen FK et al. Bladder cancer exosomes contain EDIL-3/Del1 and facilitate cancer progression. J Urol. 2014; 192: 583–92. [PubMed Abstract].
   Google Scholar
• Yang L, Wu XH, Wang D, Luo CL, Chen LX. Bladder cancer cell-derived exosomes inhibit tumour cell apoptosis and induce cell proliferation in vitro. Mol Med Rep. 2013; 8: 1272–8. [PubMed Abstract].
   Google Scholar
• Ostenfeld MS, Jeppesen DK, Laurberg JR, Boysen AT. Cellular disposal of miR23b by RAB27-dependent exosome release is linked to acquisition of metastatic properties. Cancer Res. 2014; 74: 5758–71. [PubMed Abstract].
   Google Scholar
• Yang C, Robbins PD. The roles of tumor-derived exosomes in cancer pathogenesis. Clin Dev Immunol. 2011; 2011: 1–11.
   Google Scholar
• Safaei R, Larson BJ, Cheng TC, Gibson MA, Otani S, Naerdemann W et al. Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells. Mol Cancer Ther. 2005; 4: 1595–604. [PubMed Abstract].
   Google Scholar
• Shedden K, Xie XT, Chandaroy P, Chang YT, Rosania GR. Expulsion of small molecules in vesicles shed by cancer cells: association with gene expression and chemosensitivity profiles. Cancer Res. 2003; 63: 4331–7. [PubMed Abstract].
   Google Scholar
• Panagopoulos K, Cross-Knorr S, Dillard C, Pantazatos D, Del Tatto M, Mills D et al. Reversal of chemosensitivity and induction of cell malignancy of a non-malignant prostate cancer cell line upon extracellular vesicle exposure. Mol Cancer. 2013; 12: 118. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Rini BI, Atkins MB. Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol. 2009; 10: 992–1000. [PubMed Abstract].
   Google Scholar
• Rini BI. Metastatic renal cell carcinoma: many treatment options, one patient. J Clin Oncol. 2009; 27: 3225–34. [PubMed Abstract].
   Google Scholar
• Kohli M, Qin R, Jimenez R, Dehm SM. Biomarker-based targeting of the androgen-androgen receptor axis in advanced prostate cancer. Adv Urol. 2012; 2012: 781459. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Richter E, Masuda K, Cook C, Ehrich M, Tadese AY, Li H et al. A role for DNA methylation in regulating the growth suppressor PMEPA1 gene in prostate cancer. Epigenetics. 2007; 2: 100–9. [PubMed Abstract].
   Google Scholar
• Pascucci L, Coccè V, Bonomi A. Paclitaxel is incorporated by mesenchymal stromal cells and released in exosomes that inhibit in vitro tumor growth: a new approach for drug delivery. J Control Release. 2014; 192: 262–70. [PubMed Abstract].
   Google Scholar
• D'Souza-Schorey C, Clancy JW. Tumor-derived microvesicles: shedding light on novel microenvironment modulators and prospective cancer biomarkers. Genes Dev. 2012; 26: 1287–99. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar